Vincerx Pharma, Inc. (VINC)
Sector: Biotechnology
Industry: Biotechnology
Vincerx Pharma, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 663 |
| Nov 12, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 5,500 |
| Nov 10, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 2,111 |
| Nov 9, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 177 |
| Nov 6, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 1,070 |
| Nov 5, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 1,870 |
| Nov 4, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 428 |
| Oct 29, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 1,000 |
| Oct 28, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 175 |
| Oct 27, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 2,205 |
| Oct 23, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 251 |
| Oct 22, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 460 |
| Oct 16, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 1,450 |
| Oct 9, 2026 | 0.0150 | 0.0257 | 0.0150 | 0.0257 | 10,977 |
| Oct 7, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 101 |
| Oct 5, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 104 |
| Oct 2, 2026 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 801 |
| Name | Shares | % | Source |
|---|---|---|---|
THE GOLDMAN SACHS GROUP, INC. · filed Apr 2024 | 31.6K | 0.6% | 13G |
Haas Kevin Acting Chief Financial Officer | 2.1K | 0.0% | FORM 4 |
BANK OF AMERICA CORP /DE/ 56-0906609 · filed Nov 2024 | 11 | 0.0% | 13G |
Insiders
- Haas KevinActing Chief Financial Officer
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer.
The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
1.33K
60d Avg
1.45K
90d Avg
1.52K
Vincerx Pharma, Inc. (OTC: VINC) traded at $0.0150 on Nov 16, 2026, unchanged from the previous close of $0.0150. 52-week range: $0.0100 to $0.0257. The company is in the Healthcare sector (Biotechnology).